timolol has been researched along with Macular Degeneration in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Glassman, AR | 1 |
| Gao, S; Guo, Y; Li, S; Tang, Y; Zhang, X | 1 |
| Byeon, SH; Kim, SS; Koh, HJ; Lee, CS; Lee, JH; Lee, SC | 1 |
| Fineman, MS; Garg, SJ; Hsu, J; Shahlaee, A; Spirn, MJ; Sridhar, J; Vander, J | 1 |
| Selen, F; Tekeli, O; Yanık, Ö | 1 |
| Dot, C; El Chehab, H; Giraud, JM; Le Corre, A; Ract-Madoux, G; Swalduz, B | 1 |
| Gillespie, BW; Musch, DC | 1 |
1 review(s) available for timolol and Macular Degeneration
| Article | Year |
|---|---|
Intractable Ocular Diseases and Treatment Progress.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cataract; Diabetic Retinopathy; Drug Delivery Systems; Dry Eye Syndromes; Eye Diseases; Glaucoma; Humans; Latanoprost; Macular Degeneration; Photosensitizing Agents; Timolol; Treatment Outcome; Verteporfin | 2020 |
1 trial(s) available for timolol and Macular Degeneration
| Article | Year |
|---|---|
[Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections].
Topics: Acetazolamide; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Bevacizumab; Brimonidine Tartrate; Chemoprevention; Clonidine; Drug Combinations; Female; Humans; Hypotonic Solutions; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular; Treatment Outcome | 2012 |
5 other study(ies) available for timolol and Macular Degeneration
| Article | Year |
|---|---|
Are P Values Enough?
Topics: Humans; Macular Degeneration; Sulfonamides; Thiophenes; Timolol | 2020 |
EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Topics: Administration, Topical; Aged; Angiogenesis Inhibitors; Bevacizumab; Drug Combinations; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea; Macular Degeneration; Male; Ophthalmic Solutions; Ranibizumab; Retrospective Studies; Sulfonamides; Thiophenes; Timolol; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2019 |
Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
Topics: Administration, Topical; Aged; Aged, 80 and over; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macular Degeneration; Male; Prospective Studies; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Assessment; Severity of Illness Index; Sulfonamides; Thiophenes; Timolol; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Assessment of the Anterior Chamber Flare and Macular Thickness in Patients Treated with Topical Antiglaucomatous Drugs.
Topics: Administration, Topical; Anterior Chamber; Antihypertensive Agents; Bimatoprost; Female; Glaucoma; Humans; Latanoprost; Macular Degeneration; Male; Middle Aged; Prostaglandins F, Synthetic; Timolol | 2017 |
The state of being noninferior.
Topics: Antihypertensive Agents; Choroidal Neovascularization; Clinical Trials as Topic; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Macular Degeneration; Photochemotherapy; Practice Guidelines as Topic; Pregnadienediols; Prostaglandins F, Synthetic; Research Design; Timolol | 2006 |